New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
09:25 EDTACAD, ACAD, ACAD, JAZZ, JAZZ, JAZZ, FRX, FRX, FRX, MDCO, MDCO, MDCO, SLXP, SLXP, SLXP, VRX, VRX, VRX, VRTX, VRTX, VRTX, SGMO, SGMO, SGMO, PCYC, PCYC, PCYC, PDLI, PDLI, PDLI, ISIS, ISIS, ISIS, HZNP, HZNP, HZNP, GILD, GILD, GILD, CELG, CELG, CELG, BIIB, BIIB, BIIB, BDSI, BDSI, BDSI, NKTR, NKTR, NKTRPiper Jaffray's technical analyst holds an analyst/industry conference call
Senior Technical Analyst Johnson provides an overview of the firm's covered universes, Biotech & Specialty Pharmaceuticals, from the viewpoint of a technical analyst on an Analyst/Industry conference call to be held on January 21 at 10 am.
News For ACAD;BDSI;BIIB;CELG;GILD;HZNP;ISIS;PDLI;PCYC;SGMO;VRTX;VRX;SLXP;MDCO;FRX;JAZZ;NKTR From The Last 14 Days
Check below for free stories on ACAD;BDSI;BIIB;CELG;GILD;HZNP;ISIS;PDLI;PCYC;SGMO;VRTX;VRX;SLXP;MDCO;FRX;JAZZ;NKTR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
August 20, 2014
07:07 EDTVRXSome Valeant shareholders express uncertainty over Allergan deal, Reuters says
Subscribe for More Information
07:04 EDTSLXPSalix buyout price could be near $192 per share, says William Blair
William Blair believes a combined Allergan (AGN) and Salix (SLXP) would be very attractive. The firm estimates a potential takeover price for Salix towards the high end of its $176-$192 per share range. Salix rose 16% yesterday to $160.80 after Wall Street Journal reported that Allergan approached the company and at least one other about a takeover.
August 19, 2014
17:14 EDTVRX, SLXPOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTVRX, SLXPAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
16:00 EDTGILDOptions Update; August 19, 2014eBay
iPath S&P 500 VIX Short-Term Futures down 28c to 27.52. Option volume leaders: AAPL C HD PBR GILD AA NFLX TWTR TSLA EBAY according to Track Data.
14:40 EDTSLXPSterne Agee says Allergan could pay up to $190 for Salix and still be accretive
Subscribe for More Information
14:11 EDTPCYCPharmacyclics weakness on safety issues overdone, says Deutsche Bank
Subscribe for More Information
13:28 EDTJAZZ, SLXPJazz moves higher after WSJ report of Salix approach by Allergan
Subscribe for More Information
13:15 EDTSLXPSalix options active after WSJ report of Allergan approach
Subscribe for More Information
13:13 EDTSLXP, VRXAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
13:06 EDTSLXPSalix jumps 6% to $147.85 after WSJ report of Allergan approach
Subscribe for More Information
13:05 EDTSLXPAllergan approached Salix about takeover, WSJ reports
10:28 EDTPDLIHigh option volume stocks
Subscribe for More Information
10:13 EDTJAZZOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:38 EDTCELG, GILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
09:07 EDTPDLIOn The Fly: Pre-market Movers
Subscribe for More Information
07:34 EDTBDSIBioDelivery Sciences management to meet with William Blair
Subscribe for More Information
07:33 EDTCELGCelgene announces publication of REVLIMID combination results
Celgene announced that results of a study evaluating the combination of REVLIMID with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone in untreated diffuse large b-cell lymphoma were published online ahead of print in the Journal of Clinical Oncology. In a phase II, open label, single arm study, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles. All patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout. The primary endpoint was event-free survival with secondary endpoints of progression free survival and overall survival. A one-stage binomial design was used to assess the efficacy and tolerability of REVLIMID with R-CHOP. Of the 64 patients enrolled, 60 were eligible for response evaluation. In these patients, the overall response rate was 98% with 80% achieving a complete response. The 24-month EFS, which was identical to PFS, and OS rates were 59% and 78%, respectively. The company said, "This study demonstrated that the addition of lenalidomide to conventional R-CHOP resulted in similar PFS rates and OS rates between sub-types. This is intriguing as patients with the non-GCB phenotype have traditionally experienced poorer outcomes. The results of this study support further evaluation of this regimen in this sub-type of DLBCL.
07:20 EDTJAZZJazz Pharmaceuticals initiated with an Overweight at JPMorgan
Subscribe for More Information
07:02 EDTSLXPSalix announces early termination of HSR Waiting Period for Cosmo transaction
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use